261 related articles for article (PubMed ID: 32083739)
1. Efficacy of late concurrent hypofractionated radiotherapy in advanced melanoma patients failing anti-PD-1 monotherapy.
Funck-Brentano E; Baghad B; Fort M; Aouidad I; Roger A; Beauchet A; Otmezguine Y; Blom A; Longvert C; Boru B; Saiag P
Int J Cancer; 2020 Sep; 147(6):1707-1714. PubMed ID: 32083739
[TBL] [Abstract][Full Text] [Related]
2. Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG.
Knispel S; Stang A; Zimmer L; Lax H; Gutzmer R; Heinzerling L; Weishaupt C; Pföhler C; Gesierich A; Herbst R; Kaehler KC; Weide B; Berking C; Loquai C; Utikal J; Terheyden P; Kaatz M; Schlaak M; Kreuter A; Ulrich J; Mohr P; Dippel E; Livingstone E; Becker JC; Weichenthal M; Chorti E; Gronewold J; Schadendorf D; Ugurel S
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32371460
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Large Use of Combined Hypofractionated Radiotherapy in a Cohort of Anti-PD-1 Monotherapy-Treated Melanoma Patients.
Saiag P; Molinier R; Roger A; Boru B; Otmezguine Y; Otz J; Valery CA; Blom A; Longvert C; Beauchet A; Funck-Brentano E
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077606
[TBL] [Abstract][Full Text] [Related]
4. Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study.
Umeda Y; Yoshikawa S; Kiniwa Y; Maekawa T; Yamasaki O; Isei T; Matsushita S; Nomura M; Nakai Y; Fukushima S; Saito S; Takenouchi T; Tanaka R; Kato H; Otsuka A; Matsuya T; Baba N; Nagase K; Inozume T; Onuma T; Kuwatsuka Y; Fujimoto N; Kaneko T; Onishi M; Namikawa K; Yamazaki N; Nakamura Y
Eur J Cancer; 2021 Nov; 157():361-372. PubMed ID: 34563991
[TBL] [Abstract][Full Text] [Related]
5. Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort.
Bai X; Kim M; Kasumova G; Si L; Tang B; Cui C; Yang X; Wei X; Cohen J; Lawrence D; Freedman C; Fadden R; Rubin K; Sharova T; Frederick D; Flaherty K; Sullivan R; Guo J; Boland G
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33632901
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic radiosurgery combined with anti-PD1 for the management of melanoma brain metastases: A retrospective study of safety and efficacy.
Carron R; Gaudy-Marqueste C; Amatore F; Padovani L; Malissen N; Balossier A; Loundou A; Bonnet N; Muracciole X; Régis JM; Grob JJ
Eur J Cancer; 2020 Aug; 135():52-61. PubMed ID: 32535348
[TBL] [Abstract][Full Text] [Related]
7. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma.
Curti B; Crittenden M; Seung SK; Fountain CB; Payne R; Chang S; Fleser J; Phillips K; Malkasian I; Dobrunick LB; Urba WJ
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32467299
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity.
Minniti G; Anzellini D; Reverberi C; Cappellini GCA; Marchetti L; Bianciardi F; Bozzao A; Osti M; Gentile PC; Esposito V
J Immunother Cancer; 2019 Apr; 7(1):102. PubMed ID: 30975225
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of combined hypo-fractionated radiotherapy and anti-PD-1 monotherapy in difficult-to-treat advanced melanoma patients.
Roger A; Finet A; Boru B; Beauchet A; Mazeron JJ; Otzmeguine Y; Blom A; Longvert C; de Maleissye MF; Fort M; Funck-Brentano E; Saiag P
Oncoimmunology; 2018; 7(7):e1442166. PubMed ID: 30034949
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma.
Ogata D; Haydu LE; Glitza IC; Patel SP; Tawbi HA; McQuade JL; Diab A; Ekmekcioglu S; Wong MK; Davies MA; Amaria RN
Cancer Med; 2021 Apr; 10(7):2293-2299. PubMed ID: 33686688
[TBL] [Abstract][Full Text] [Related]
12. Discontinuation of anti-PD-1 monotherapy in advanced melanoma-Outcomes of daily clinical practice.
van Zeijl MCT; van den Eertwegh AJM; Wouters MWJM; de Wreede LC; Aarts MJB; van den Berkmortel FWPJ; de Groot JB; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; van der Hoeven JJM; Haanen JBAG
Int J Cancer; 2022 Jan; 150(2):317-326. PubMed ID: 34520567
[TBL] [Abstract][Full Text] [Related]
13. Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma.
Pokorny R; McPherson JP; Haaland B; Grossmann KF; Luckett C; Voorhies BN; Sageser DS; Wallentine J; Tolman Z; Hu-Lieskovan S; Swami U
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33500258
[TBL] [Abstract][Full Text] [Related]
14. Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial.
Mulder EEAP; de Joode K; Litière S; Ten Tije AJ; Suijkerbuijk KPM; Boers-Sonderen MJ; Hospers GAP; de Groot JWB; van den Eertwegh AJM; Aarts MJB; Piersma D; van Rijn RS; Kapiteijn E; Vreugdenhil G; van den Berkmortel FWPJ; Hoop EO; Franken MG; Ryll B; Rutkowski P; Sleijfer S; Haanen JBAG; van der Veldt AAM
BMC Cancer; 2021 Mar; 21(1):323. PubMed ID: 33765967
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases.
Parakh S; Park JJ; Mendis S; Rai R; Xu W; Lo S; Drummond M; Rowe C; Wong A; McArthur G; Haydon A; Andrews MC; Cebon J; Guminski A; Kefford RF; Long GV; Menzies AM; Klein O; Carlino MS
Br J Cancer; 2017 Jun; 116(12):1558-1563. PubMed ID: 28524161
[TBL] [Abstract][Full Text] [Related]
16. Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.
Jansen YJL; Rozeman EA; Mason R; Goldinger SM; Geukes Foppen MH; Hoejberg L; Schmidt H; van Thienen JV; Haanen JBAG; Tiainen L; Svane IM; Mäkelä S; Seremet T; Arance A; Dummer R; Bastholt L; Nyakas M; Straume O; Menzies AM; Long GV; Atkinson V; Blank CU; Neyns B
Ann Oncol; 2019 Jul; 30(7):1154-1161. PubMed ID: 30923820
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 Trial of Nivolumab Combined With Stereotactic Body Radiation Therapy in Patients With Metastatic or Locally Advanced Inoperable Melanoma.
Sundahl N; Seremet T; Van Dorpe J; Neyns B; Ferdinande L; Meireson A; Brochez L; Kruse V; Ost P
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):828-835. PubMed ID: 30951807
[TBL] [Abstract][Full Text] [Related]
18. Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response.
Dimitriou F; Zaremba A; Allayous C; Kähler KC; Gerard CL; Festino L; Schäfer S; Toussaint F; Heinzerling L; Hassel JC; Ascierto PA; Michielin O; Hauschild A; Lebbe C; Livingstone E; Ramelyte E; Cheng PF; Dummer R; Mangana J
Eur J Cancer; 2021 May; 149():37-48. PubMed ID: 33823361
[TBL] [Abstract][Full Text] [Related]
19.
Parakh S; Musafer A; Paessler S; Witkowski T; Suen CSNLW; Tutuka CSA; Carlino MS; Menzies AM; Scolyer RA; Cebon J; Dobrovic A; Long GV; Klein O; Behren A
Front Immunol; 2021; 12():672521. PubMed ID: 34177913
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety data for checkpoint inhibitors in advanced melanoma under real-life conditions: A monocentric study conducted in Nice from 2010 to 2016.
Taquin H; Fontas E; Massol O; Chevallier P; Balloti R; Beranger G; Lacour JP; Passeron T; Montaudié H
Ann Dermatol Venereol; 2018 Nov; 145(11):649-658. PubMed ID: 30098818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]